NL-OMON36388已完成不适用
An open-label, dose escalating Phase Ib study for the assessment of safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple intravenous doses of GLPG0187 in subjects with solid tumors. - Phase Ib study with GLPG0187 in subjects with solid tumors.
Galapagos SAS0 个研究点目标入组 19 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Pathologically confirmed diagnosis of advanced, recurrent, or metastatic cancer who are refractory to standard therapy or for whom no standard therapy exist.
- •2. Age >= 18 years.
- •3. Measurable (according to RECIST 1.1) and evaluable disease as determined by the Investigator.
- •4. ECOG Performance Status <= 2.
- •5. Estimated life expectancy of at least 12 weeks.
- •6. Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to <= Grade 2.
- •7. Written informed consent according to local guidelines.
排除标准
- •Prior Treatment:
- •1. Less than 4 weeks since the last treatment with other cancer therapies, (i.e. endocrine therapy, immunotherapy, chemotherapy, etc.), and < 6 weeks for nitrosoureas and Mitomycin C.
- •2. Prior therapy with integrin receptor antagonists.;Current Treatment:
- •3. Chronic daily treatment with corticosteroids (dose of * 10 mg/day methylprednisolone or equivalent), with the exception of inhaled steroids.
- •4. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study.;Hematology, coagulation and biochemistry:
- •5. Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count <100 x 109/L or hemoglobin < 6 mmol/L.
- •6. Inadequate liver function, defined as:
- •Serum (total) bilirubin > 2 x the Upper Limit of Normal (ULN) for the institution;
- •Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN (> 5 x ULN in subjects with liver metastases);
- •Alkaline phosphatase levels > 2.5 x ULN (> 5 x ULN in subjects with liver metastases, or > 10 x ULN in subjects with bone metastases).
- •7. Inadequate renal function, defined as:
- •Serum creatinine > 1.5 x ULN
- •Urine dipstick for proteinuria > 2+.;Other:
- •8. Clinically symptomatic or progressive brain metastases
- •9. Clinical Leptomeningeal metastases
- •10. Pregnancy or lactation. Urine pregnancy test to be assessed within 7 days prior to study treatment start.
- •11. For women of childbearing potential (defined as <2 years after last menstruation and not surgically sterile): absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).
- •12. Major surgical procedure (including open biopsy, excluding central line IV and portacath) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- •13. Congestive heart failure NYHA Class III and IV. Cardiac arrhythmias (except for atrioventricular block type I, Mobitz type, and II, Wenckebach type) signs and symptoms of relevant cardiovascular disease.
- •14. Known hypersensitivity to any of the study drugs or excipients.
- •15. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect subject compliance or place the subject at high risk from treatment-related complications.
研究者
相似试验
尚未招募
不适用
An open-label, phase Ib, dose-escalation trial on the safety, tolerability, pharmacokinetics, immunogenicity, biological effects and antitumor activity of EMD 521873 in combination with local irradiation (20 Gy) of primary tumors or metastases in subjects with non-small cell lung cancer stage IIIb with malignant pleural effusion or stage IV with disease control (partial response or stable disease) after application of 4 cycles of platinum-based, first-line chemotherapy.non-small cell lung carcinoma10038666Lung cancerNL-OMON34011Merck KGaA24
进行中（未招募）
不适用
An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung canceron-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months.EUCTR2004-004252-40-BEovartis Pharma Services AG42
进行中（未招募）
不适用
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemia - N/ARelapsed or refractory leukemia in paediatric patientsEUCTR2008-006931-11-SEovartis Pharma Services AG22
进行中（未招募）
不适用
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemia - N/Ain pediatric patients with relapsed or refractory leukemiaEUCTR2008-006931-11-NLovartis Pharma Services AG22
已完成
2 期
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemiaRelapsed/refractory leukemia10024324NL-OMON39282ovartis5